Halofantrine and chloroquine inhibit CYP2D6 activity in healthy Zambians.
OBJECTIVE
To determine the effect of therapeutic loading doses of halofantrine and chloroquine on CYP2D6 activity in healthy black Zambians.


METHODS
Twenty healthy black male Zambians were phenotyped for CYP2D6 activity by measuring the debrisoquine/4-hydroxydebrisoquine ratio in a 0-8 h urine sample after a 10 mg oral dose of debrisoquine hemi-sulphate. The subjects (all 'extensive metabolizer' phenotype with respect to CYP2D6) were randomized into two groups of 10, and 24 h later one group received 1500 mg halofantrine hydrochloride and the other group 1500 mg chloroquine phosphate both orally in divided doses. All subjects were given further 10 mg doses of debrisoquine at 2 h, 1 week and 2 weeks after the last dose of the antimalarial drug, and phenotyped as described above.


RESULTS
The median debrisoquine/4-hydroxydebrisoquine 0-8 h urinary ratio was increased by halofantrine (1.39 to 6.05; P<0.01; 95% confidence intervals 4.00-11.7) and chloroquine (1.96 to 3.91; P<0.01; 95% confidence intervals 1.34-2.66) when debrisoquine was given 2 h after treatment. The decrease in CYP2D6 activity remained statistically significant for 1 week after both drugs. Halofantrine was a significantly more potent inhibitor of CYP2D6 than chloroquine (P=0.037). Phenocopying occurred in two subjects taking halofantrine and one taking chloroquine (i.e. the debrisoquine/4-hydroxydebrisoquine ratios became consistent with the poor metabolizer phenotype).


CONCLUSIONS
Given in therapeutic loading doses, both halofantrine and chloroquine caused significant inhibition of CYP2D6 activity in healthy black Zambians. With respect to halofantrine, this finding reinforces the recommendation that its combination with other drugs known to prolong the QT interval should be avoided, especially those that are metabolized significantly by CYP2D6.
Simooya
O O
OO
University of Sheffield Department of Medicine and Pharmacology, Royal Hallamshire Hospital, Sheffield S10 2JF, UK.
Sijumbil
G
G
Lennard
M S
MS
Tucker
G T
GT
D000284:Administration, Oral; D000328:Adult; D000962:Antimalarials / Q000494:pharmacology*; D044383:Black People; D002738:Chloroquine / Q000494:pharmacology*; D002849:Chromatography, Gas; D019389:Cytochrome P-450 CYP2D6 / Q000378:metabolism; D065690:Cytochrome P-450 CYP2D6 Inhibitors; D003647:Debrisoquin / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000652:urine; D006801:Humans; D008099:Liver / Q000187:drug effects / Q000201:enzymology; D008297:Male; D010616:Phenanthrenes / Q000494:pharmacology*; D015024:Zambia / Q000453:epidemiology
D000962:Antimalarials; D065690:Cytochrome P-450 CYP2D6 Inhibitors; D010616:Phenanthrenes; C012359:4-hydroxydebrisoquin; D002738:Chloroquine; D019389:Cytochrome P-450 CYP2D6; C023768:halofantrine; D003647:Debrisoquin